Expert Interview
Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with an allergist
Ticker(s): CLDXInstitution: Charité – Universitätsmedizin Berlin
- Professor of Dermatology, Assistant Medical Director of the department of Dermatology, Venereology and principal investigator in the Dermatological Allergology lab at the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany.
- Treats 1200 patients per year with Chronic Urticaria (900 spontaneous CU & 90% are refractory to antihistamines.
- PI on several major urticaria trials; Research focuses on mast cell biology, neuroimmunology, inflammation and innate immunity with a clinical focus on pruritus and mast cell mediated diseases.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
